-A A +A
February 26, 2019

Canada is not a “free rider” on drug pricing according to a new report from the C.D. Howe Institute. In “High Drug Prices, Big R&D Spenders and “Free Riders”: Canada in the Topsy Turvy World of Pharmaceuticals”, authors Åke Blomqvist and Rosalie Wyonch find that relative to its peers, Canada does not free ride on US research and development spending.

Åke Blomqvist
Åke Blomqvist

Health Policy Scholar, C.D. Howe Institute

Åke Blomqvist received his undergraduate education in his native Sweden, and a PhD from Princeton University in 1971. He is Professor Emeritus at the University of Western Ontario where he taught between 1968 and 2002.

Rosalie Wyonch
Rosalie Wyonch

Rosalie has a Master of Arts in Economics and a Bachelor of Arts in Honours Mathematical Economics from the University of Waterloo. Prior to joining the C.D. Howe Institute as a Policy Analyst in 2016, she was a Research Analyst at the Ontario Ministry of Finance in the Office of Economic Policy.